Skip to main content
Top

05-06-2024 | NSCLC | News

ASCO 2024

5-year update of CROWN study shows benefit of lorlatinib over crizotinib

MedNet.nl: Lorlatinib as first-line treatment for advanced ALK-positive NSCLC improves PFS compared with crizotinib. The 5-year follow-up showed that the median progression-free survival in the lorlatinib arm had not yet been reached, while that in the crizotinib arm was 9.1 months. Never before has a study in advanced NSCLC seen such a long median progression-free survival, researchers from the CROWN study told the ASCO conference.

Related topics

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more